Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a ... manufacture and sale of enzyme and protein products ... today announced financial results for the quarter ended ... this press release should be read in conjunction ...
... SynCo Bio Partners B.V., one of the leading GMP contract ... is again fully operational and SynCo has produced and released ... expansion of its Class A zone.   The ... in SynCo,s strategy in supporting its clients with new product ...
... for gram, novel carbon nanofiber-filled coatings devised by researchers ... and Texas A&M University outperformed conventional flame retardants used ... by at least 160 percent and perhaps by as ... reported in the journal Polymer ,* suggest that ...
Cached Biology Technology:Dyadic International Reports 2011 Second Quarter Financial Results 2Dyadic International Reports 2011 Second Quarter Financial Results 3Dyadic International Reports 2011 Second Quarter Financial Results 4Dyadic International Reports 2011 Second Quarter Financial Results 5Dyadic International Reports 2011 Second Quarter Financial Results 6Dyadic International Reports 2011 Second Quarter Financial Results 7SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:4/15/2014)... 2014, Irvine, Calif. UC Irvine neurobiologists have found ... when transplanted into the brains of mice with the ... is published in the journal Stem Cells Research ... to work in two different mouse models. , ... dementia, is associated with accumulation of the protein amyloid-beta ...
(Date:4/15/2014)... know as early as 2020 how high sea levels ... team of researchers including Florida International University scientist Rene ... Science Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research ... in ecosystems from coral reefs to deserts, mountains to ... sea level rise is one of the most certain ...
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Long-term predictions for Miami sea level rise could be available relatively soon 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... insect brains, mouth bacteria behaving badly and the hundreds ... just some of the highlights at the Society for ... The annual event takes place on 6-9 September at ... international experts will present cutting-edge scientific research covering a ...
... Carolina State University shows that a species of shellfish widely ... actually increased in size, despite and possibly because of ... found indicates that human activity does not necessarily mean that ... species even a species that people relied on as ...
... filter-feeder, that anchors itself to the sea bed, offers new ... Ice Sheet a region that is thought to be ... for the Census of Antarctic Marine Life (CAML), scientists from ... coastal and deep sea regions around the continent and from ...
Cached Biology News:Archaeological study shows human activity may have boosted shellfish size 2Marine animals suggest evidence for a trans-Antarctic seaway 2
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
Biology Products: